6:24AM Acorda Therapeutics beats by $0.05, beats on revs; reaffirms FY13 Ampyra net rev guidance (ACOR) 37.97 : Reports Q2 (Jun) earnings of $0.25 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.20; revenues rose 15.1% year/year to $87.1 mln vs the $82.51 mln consensus.
"AMPYRA sales rebounded strongly in the second quarter, as expected, based on underlying product demand and a return to normal inventory levels by the end of the first quarter. Quarterly sales patterns are uneven, and we do not expect to see the same rate of quarter-over-quarter growth for the rest of the year. We are reiterating our full-year AMPYRA net revenue guidance of $285-$315 million."
News 
Market Data 
Discover 
AI
